Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

BACKGROUND: Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, acces...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cochrane Database Syst Rev
Main Authors: Piechotta, Vanessa, Jakob, Tina, Langer, Peter, Monsef, Ina, Scheid, Christof, Estcourt, Lise J, Ocheni, Sunday, Theurich, Sebastian, Kuhr, Kathrin, Scheckel, Benjamin, Adams, Anne, Skoetz, Nicole
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2019
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876545/
https://ncbi.nlm.nih.gov/pubmed/31765002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013487
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados